Showing results (251-260 of 941) with videos related to

Sort By:
Pageof 95
Neurology and Therapy|August 3, 2021
Role of Brain Natriuretic Peptide in the Prediction of Early Postoperative Seizures Following Surgery for Traumatic Acute Subdural Hematoma: A Prospective StudyMehdi Chihi, Marvin Darkwah Oppong, Carlos M Quesada, et al.
Neurology and Therapy|September 22, 2022
Rapid Onset and Sustained Efficacy of Lasmiditan Among Japanese Patients with Migraine: Prespecified Analyses of a Randomized Controlled TrialYasuhiko Matsumori, Mika Komori, Yuka Tanji, et al.
Neurology and Therapy|September 17, 2022
Elderly-Onset Paroxysmal Kinesigenic Dyskinesia: A Case ReportLulu Yao, Wei Liang, Shanshan Mei, et al.
Neurology and Therapy|January 12, 2022
Adherence to and Persistence with Disease-Modifying Therapies for Multiple Sclerosis Over 24 Months: A Retrospective Claims AnalysisGabriel Pardo, Elmor D Pineda, Carmen D Ng, et al.
Neurology and Therapy|November 20, 2021
Endovascular Treatment in Acute Ischemic Stroke with Large Vessel Occlusion According to Different Stroke Subtypes: Data from ANGEL-ACT RegistryXiaochuan Huo, Dapeng Sun, Raynald, et al.
Neurology and Therapy|December 10, 2021
Erenumab Decreases Headache-Related Sick Leave Days and Health Care Visits: A Retrospective Real-World Study in Working Patients with MigraineHenri Autio, Timo Purmonen, Samu Kurki, et al.
Neurology and Therapy|November 2, 2022
Understanding the Symptom Burden and Impact of Myasthenia Gravis from the Patient's Perspective: A Qualitative StudyKristi Jackson, Anju Parthan, Miranda Lauher-Charest, et al.
Neurology and Therapy|November 5, 2022
Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple SclerosisBrittney Lager, Jacob Liseno, Ivan Božin, et al.
Neurology and Therapy|September 6, 2022
Expert-Agreed Practical Recommendations on the Use of CladribineVirginia Meca-Lallana, José M García Domínguez, Rocío López Ruiz, et al.
Neurology and Therapy|February 20, 2021
Ubrogepant for the Acute Treatment of Migraine: Pooled Efficacy, Safety, and Tolerability From the ACHIEVE I and ACHIEVE II Phase 3 Randomized TrialsSusan Hutchinson, David W Dodick, Christina Treppendahl, et al.
Pageof 95